Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.

MGMT Gene Silencing and Benefit from Temozolomide in Glioblastoma

Open access

Abstract

BACKGROUND: Epigenetic silencing of the MGMT (O6-methylguanine-DNA methyltransferase) DNA-repair gene by promoter methylation compromises DNA repair and has been associated with longer survival in patients with glioblastoma who receive alkylating agents. METHODS: We tested the relationship between MGMT silencing in the tumor and the survival of patients who were enrolled in a randomized trial comparing radiotherapy alone with radiotherapy combined with concomitant and adjuvant treatment with temozolomide. The methylation status of the MGMT promoter was determined by methylation-specific polymerase-chain-reaction analysis. RESULTS: The MGMT promoter was methylated in 45 percent of 206 assessable cases. Irrespective of treatment, MGMT promoter methylation was an independent favorable prognostic factor (P<0.001 by the log-rank test; hazard ratio, 0.45; 95 percent confidence interval, 0.32 to 0.61). Among patients whose tumor contained a methylated MGMT promoter, a survival benefit was observed in patients treated with temozolomide and radiotherapy; their median survival was 21.7 months (95 percent confidence interval, 17.4 to 30.4), as compared with 15.3 months (95 percent confidence interval, 13.0 to 20.9) among those who were assigned to only radiotherapy (P=0.007 by the log-rank test). In the absence of methylation of the MGMT promoter, there was a smaller and statistically insignificant difference in survival between the treatment groups. CONCLUSIONS: Patients with glioblastoma containing a methylated MGMT promoter benefited from temozolomide, whereas those who did not have a methylated MGMT promoter did not have such a benefit.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1056/nejmoa043331

Cites

22 of 22 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 22 references

Research works printed but not linked: 9

  1. Ochs K, 2000, Cancer Res, 60, 5815
  2. Liu L, 1996, Cancer Res, 56, 5375
  3. Belanich M, 1996, Cancer Res, 56, 783
  4. Silber JR, 1999, Clin Cancer Res, 5, 807
  5. Qian XC, 1997, Cancer Res, 57, 3672
  6. Esteller M, 1999, Cancer Res, 59, 793
  7. Palmisano WA, 2000, Cancer Res, 60, 5954
  8. Fritz G, 1991, Mol Cell Biol, 11, 4660, 10.1128/MCB.11.9.4660 · doi:10.1128/mcb.11.9.4660
  9. Quinn JA, 2003, Prog Proc Am Soc Clin Oncol, 22, 103

Cited by

See all 7,405

Metadata

Authors
Hegi, M. E., Diserens, A.-C., Gorlia, T., Hamou, M.-F., de Tribolet, N., Weller, M., Kros, J. M., Hainfellner, J. A., Mason, W., Mariani, L., Bromberg, J. E. C., Hau, P., Mirimanoff, R. O., Cairncross, J. G., Janzer, R. C., & Stupp, R.
Affiliations
  • Centre Hospitalier Universitaire Vaudois (CH)
  • European Organisation for Research and Treatment of Cancer (NL)
  • University of Tübingen (DE)
  • Erasmus MC (NL)
  • Medical University of Vienna (AT)
  • Princess Margaret Cancer Centre (CA)
  • University Hospital of Bern (CH)
  • University Medical Center Utrecht (NL)
  • University of Regensburg (DE)
  • University of Calgary (CA)
Venue
New England Journal of Medicine
Published
2005-03-10
Volume
352
Issue
10
Pages
997-1003
ISSN
  • 0028-4793 (ISSN-L)
  • 1533-4406
OpenAlex
W2105100844
Cited by
7,405
References
22
Citations by year
2026: 344 · 2025: 342 · 2024: 383 · 2023: 407 · 2022: 444 · 2021: 525 · 2020: 442 · 2019: 391 · 2018: 361 · 2017: 390 · 2016: 391 · 2015: 391 · 2014: 360 · 2013: 369 · 2012: 372
FWCI
84.02
Type
journal article
Language
en
Open access
Locations
  • New England Journal of Medicine (publishedVersion)
  • PubMed (publishedVersion)
  • EUR Research Repository (Erasmus University Rotterdam) (publishedVersion)
  • SERVAL (Université de Lausanne) (publishedVersion, other-oa)
  • IRIS (submittedVersion)
  • EUR Research Repository (Erasmus University Rotterdam) (submittedVersion)
  • University of Regensburg Publication Server (University of Regensburg) (submittedVersion)
  • University of Groningen research database (University of Groningen / Centre for Information Technology) (submittedVersion)
Topics
  • Health Sciences › Medicine › Oncology › Glioma Diagnosis and Treatment
  • Health Sciences › Medicine › Oncology › PARP inhibition in cancer therapy
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Epigenetics and DNA Methylation
Keywords
glioblastoma, MGMT promoter methylation, O6-methylguanine-DNA methyltransferase, temozolomide, epigenetic silencing, DNA repair, alkylating agents, radiotherapy, survival benefit, prognostic factors
MeSH terms
Temozolomide, Brain Neoplasms, Dacarbazine, Glioblastoma, Humans, Promoter Regions, Genetic, Survival Analysis, Randomized Controlled Trials as Topic, Polymerase Chain Reaction, Chemotherapy, Adjuvant, Disease-Free Survival, Antineoplastic Agents, Alkylating, DNA Methylation, O(6)-Methylguanine-DNA Methyltransferase, Gene Silencing

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: MGMT Gene Silencing and Benefit from Temozolomide in Glioblastoma. https://app.cochat.ai/papers/10.1056/nejmoa043331
The paper
Hegi, M. E., Diserens, A.-C., Gorlia, T., Hamou, M.-F., de Tribolet, N., Weller, M., Kros, J. M., Hainfellner, J. A., Mason, W., Mariani, L., Bromberg, J. E. C., Hau, P., Mirimanoff, R. O., Cairncross, J. G., Janzer, R. C., & Stupp, R. (2005). MGMT Gene Silencing and Benefit from Temozolomide in Glioblastoma. New England Journal of Medicine. https://doi.org/10.1056/nejmoa043331

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.